Magnitude Biosciences is a contract research organisation (CRO) based in Sedgefield, UK, specialising in in vivo drug discovery using C.elegans. Its patented WormGazer® technology and VivoScan™ platform provides rapid, high-quality data on compound efficacy, toxicity, and mechanism of action - helping biotech and pharma companies make better decisions, faster. With over 120 projects delivered, Magnitude is trusted by clients in drug discovery, health and nutrition, and ageing biology.
Magnitude Biosciences: Venture Capital Funding History
Magnitude Biosciences
Magnitude Biosciences
- Life Sciences
- Durham, United Kingdom
- £1.3m
- magnitudebiosciences.com
- Update Information
More venture news
- 26 Oct 2026

adsilicoadsilico unlocks a £10m Series A round led by PXN Ventures for virtual testing of implantable medical devices
Series ALife Sciences - 26 Oct 2026

imphatecimphatec raises a £1.5m seed round led by SynBioVen to develop customisable-dose implants for chronic conditions
SeedLife Sciences - 15 Oct 2026

OMass TherapeuticsOMass Therapeutics raises a £230m Series C round from VCs including Bain Capital to develop small molecule therapeutics with drug discovery platform
Series CLife Sciences
